argenx

A chessboard with blocks that read MA
Biotech

Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug

Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
James Waldron , Angus Liu Jul 27, 2026 6:08am
Paragliding near Tu Le valley with landscape with green and yellow rice fields and blue cloudy sky North- Vietnam

Former Roche oncology head turns to Tubulis—Chutes & Ladders

Jan 9, 2026 8:30am
Sunrise over foggy forest in Tuscany Italy

Versant's Dayra dawns with $50M Biogen pact

Nov 24, 2025 10:28am
business targets illustration

Argenx's $1.5B pact to turn macrocyclic peptides to new targets

Jul 1, 2025 8:00am
An arrow incrementally going up stairs before pointing straight up Blue background

Leo's eczema prospect hits primary endpoint in phase 2b

May 9, 2025 7:30am
target reach ladder climb meet win beat competition

J&J's phase 2 Sjögren's data support FcRn strategy

Jun 17, 2024 8:47am